1.70
Schlusskurs vom Vortag:
$1.68
Offen:
$1.72
24-Stunden-Volumen:
361.45K
Relative Volume:
0.40
Marktkapitalisierung:
$184.08M
Einnahmen:
$27.08M
Nettoeinkommen (Verlust:
$-37.00M
KGV:
-3.2692
EPS:
-0.52
Netto-Cashflow:
$-18.46M
1W Leistung:
+5.59%
1M Leistung:
+4.29%
6M Leistung:
-32.27%
1J Leistung:
+25.93%
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
Firmenname
Aclaris Therapeutics Inc
Sektor
Branche
Telefon
484-324-7933
Adresse
701 LEE ROAD, WAYNE, PA
Vergleichen Sie ACRS mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
ACRS
Aclaris Therapeutics Inc
|
1.70 | 181.91M | 27.08M | -37.00M | -18.46M | -0.52 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-07-10 | Fortgesetzt | Piper Sandler | Overweight |
2025-05-28 | Eingeleitet | Wedbush | Outperform |
2025-03-18 | Fortgesetzt | Cantor Fitzgerald | Overweight |
2024-12-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
2024-11-20 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
2024-11-19 | Hochstufung | BTIG Research | Neutral → Buy |
2024-11-19 | Hochstufung | Jefferies | Hold → Buy |
2024-11-19 | Hochstufung | Leerink Partners | Market Perform → Outperform |
2024-11-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
2024-01-22 | Herabstufung | H.C. Wainwright | Buy → Neutral |
2023-11-13 | Herabstufung | William Blair | Outperform → Mkt Perform |
2023-10-03 | Eingeleitet | Evercore ISI | Outperform |
2022-12-14 | Eingeleitet | Stifel | Buy |
2022-12-01 | Eingeleitet | Goldman | Buy |
2022-10-06 | Eingeleitet | BTIG Research | Buy |
2021-07-23 | Fortgesetzt | Jefferies | Buy |
2021-06-15 | Eingeleitet | Piper Sandler | Overweight |
2021-04-21 | Eingeleitet | H.C. Wainwright | Buy |
2019-10-22 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
2019-09-06 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
2019-06-27 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
2019-05-06 | Eingeleitet | SVB Leerink | Outperform |
2018-03-28 | Fortgesetzt | Leerink Partners | Outperform |
2018-02-09 | Eingeleitet | Guggenheim | Buy |
2017-06-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
2016-11-29 | Eingeleitet | Leerink Partners | Outperform |
2016-09-30 | Eingeleitet | JMP Securities | Mkt Outperform |
2016-06-10 | Eingeleitet | Guggenheim | Buy |
2015-11-02 | Eingeleitet | Citigroup | Buy |
2015-11-02 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Aclaris Therapeutics Inc Aktie (ACRS) Neueste Nachrichten
Momentum divergence signals in Aclaris Therapeutics Inc. chartTrend Following Ideas with Volume Confirmation - Newser
Market reaction to Aclaris Therapeutics Inc.’s recent newsFree Expert Verified Stock Trade Ideas - Newser
Using R and stats models for Aclaris Therapeutics Inc. forecasting Free Smart Trend Trading with Weekly Signals - Newser
What is the risk reward ratio of investing in Aclaris Therapeutics Inc. stockHigh-performance stocks for savvy investors - jammulinksnews.com
What are Aclaris Therapeutics Inc. company’s key revenue driversMaximize returns with effective portfolio management - jammulinksnews.com
What are analysts’ price targets for Aclaris Therapeutics Inc. in the next 12 monthsHarness the power of proven investment plans - jammulinksnews.com
What are the latest earnings results for Aclaris Therapeutics Inc.Capitalize on emerging growth stocks - jammulinksnews.com
Published on: 2025-07-28 01:01:49 - jammulinksnews.com
How Resilient Is Aclaris Therapeutics Inc. Stock During Economic DownturnsLong Term Secure Gain Stocks - Newser
Published on: 2025-07-27 19:20:18 - jammulinksnews.com
How Efficient Is Aclaris Therapeutics Inc. at Controlling Operating CostsInsider Level Guidance - Newser
What drives Aclaris Therapeutics Inc. stock priceRapidly expanding wealth - PrintWeekIndia
Aclaris Therapeutics Inc. Stock Analysis and ForecastConsistently high returns - PrintWeekIndia
What institutions are buying Aclaris Therapeutics Inc. stock nowPhenomenal returns - jammulinksnews.com
What analysts say about Aclaris Therapeutics Inc. stockFree Predictions - PrintWeekIndia
Why Aclaris Therapeutics Inc. stock attracts strong analyst attentionFree Professional Portfolio Management - Newser
LENZ Therapeutics Inc. Stock Analysis and ForecastPhenomenal capital appreciation - Autocar Professional
Is Aclaris Therapeutics Inc. a good long term investmentRapid capital growth - jammulinksnews.com
How Aclaris Therapeutics Inc. stock performs during market volatilityDaily Volume Leaders - Newser
What makes Aclaris Therapeutics Inc. stock price move sharplyEntry Level Low Risk Picks - Newser
Aclaris Therapeutics Begins Phase 1 Clinical Trial for Bispecific Antibody ATI-052 Targeting Inflammatory Diseases - Insider Monkey
13 Best Low Priced Pharma Stocks to Buy Now - Insider Monkey
Piper Sandler Begins Coverage on Aclaris Therapeutics (NASDAQ:ACRS) - Defense World
Aclaris Therapeutics' Recent Gains Improve Losses On Insider Purchases Worth US$1.50m - simplywall.st
Plus Therapeutics (NASDAQ:PSTV) vs. Aclaris Therapeutics (NASDAQ:ACRS) Head-To-Head Survey - Defense World
Aclaris Therapeutics Joins Russell 3000 and Russell 2000 Indexes - MSN
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Finanzdaten der Aclaris Therapeutics Inc-Aktie (ACRS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Aclaris Therapeutics Inc-Aktie (ACRS) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Mehra Anand | Director |
Nov 19 '24 |
Buy |
2.25 |
666,666 |
1,499,998 |
710,030 |
Walker Neal | INTERIM PRESIDENT AND CEO |
Aug 09 '24 |
Option Exercise |
0.72 |
43,548 |
31,355 |
1,356,153 |
Leonard Braden Michael | 10% Owner |
Aug 05 '24 |
Buy |
1.24 |
206,025 |
256,357 |
14,250,000 |
Leonard Braden Michael | 10% Owner |
Aug 02 '24 |
Buy |
1.29 |
167,544 |
216,400 |
14,043,975 |
Leonard Braden Michael | 10% Owner |
Jul 30 '24 |
Buy |
1.30 |
173,730 |
226,370 |
13,776,421 |
Leonard Braden Michael | 10% Owner |
Jul 31 '24 |
Buy |
1.33 |
100,000 |
132,640 |
13,876,421 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):